|
gptkbp:instanceOf
|
gptkb:psychedelic_tryptamine
gptkb:chemical_compound
|
|
gptkbp:CASNumber
|
1019-45-0
|
|
gptkbp:category
|
gptkb:Hallucinogen
gptkb:alkaloid
gptkb:serotonin_receptor_agonist
|
|
gptkbp:chemicalFormula
|
C13H18N2O
|
|
gptkbp:color
|
white to off-white
|
|
gptkbp:discoveredBy
|
gptkb:Hoshino_and_Shimodaira
|
|
gptkbp:discoveredIn
|
1936
|
|
gptkbp:duration
|
short (15–60 minutes)
|
|
gptkbp:effect
|
psychedelic
hallucinogenic
entactogenic
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:hasInChIKey
|
GMCMZNCUTQYNRU-UHFFFAOYSA-N
|
|
gptkbp:hasSMILES
|
CN(C)CCc1c[nH]c2ccc(OC)cc12
|
|
gptkbp:IUPACName
|
gptkb:2-(5-methoxy-1H-indol-3-yl)-N,N-dimethylethanamine
|
|
gptkbp:legalStatus
|
gptkb:Schedule_III_(Canada)
gptkb:Schedule_I_(United_States)
gptkb:Class_A_(United_Kingdom)
Schedule 9 (Australia)
|
|
gptkbp:mainStreet
|
gptkb:Dragon
gptkb:The_God_Molecule
Five-MeO
|
|
gptkbp:mechanismOfAction
|
gptkb:serotonin_receptor_agonist
5-HT2A receptor agonist
|
|
gptkbp:metabolism
|
gptkb:monoamine_oxidase
|
|
gptkbp:molecularWeight
|
218.30 g/mol
|
|
gptkbp:occurredIn
|
gptkb:toad_venom_(Incilius_alvarius)
various plant species
|
|
gptkbp:PubChem_CID
|
1976
CHEMBL2110612
|
|
gptkbp:relatedTo
|
gptkb:DMT
gptkb:psilocin
gptkb:bufotenin
|
|
gptkbp:riskFactor
|
risk of death in rare cases
risk of psychological distress
risk of serotonin syndrome
|
|
gptkbp:routeOfAdministration
|
injection
oral
insufflation
vaporization
|
|
gptkbp:solubility
|
slightly soluble in water
soluble in ethanol
soluble in chloroform
|
|
gptkbp:toxicity
|
high in overdose
|
|
gptkbp:UNII
|
YFQ03L43G8
|
|
gptkbp:usedIn
|
shamanic rituals
entheogenic practices
|
|
gptkbp:bfsParent
|
gptkb:DMT
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
5-MeO-DMT
|